Slide 1: 2026 Q1 Trading Update
2026 Q1 Trading Update 16 April 2026 These written materials or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require reg
Slide 2: Today’s presenters
Today’s presenters Walter Hess Daniel Wüest CEO CFO | 26Q1 Trading Update 2
Slide 3: Agenda
Agenda 1. Q1 Trading Update 2. Q&A | 26Q1 Trading Update 3
Slide 4: Highlights Q1 2026: Strong start into the year confirming guidance 2026
Highlights Q1 2026: Strong start into the year confirming guidance 2026 Strong 30.4% Rx Digital Active On track to revenue growth yoy Services with customers EBITDA growth of and 7.6% qoq growth of grew by breakeven: 10.7% yoy with 63.1% 1.0m yoy to adj. EBITDA acceleration alongside 12.6m and of CH
Slide 5: Sustained quarterly Rx revenue growth with acceleration in Q1 2026
Business update Sustained quarterly Rx revenue growth with acceleration in Q1 2026 Revenue in EURm 30.4% 90 2.0x 80 74.3 69.0 70 65.1 60 56.4 57.0 59.6 Rx growth yoy 50.5 50 in local currency 43.8 40 37.4 30 7.6% 20 10 0 Q1 2024A Q2A Q3A Q4A Q1 2025A Q2A Q3A Q4A Q1 2026A Rx growth qoq PKV pRx revenu
Slide 6: Non-Rx business drives value by continuously delivering profitable growth
Business update Non-Rx business drives value by continuously delivering profitable growth OTC/BPC Revenue +6.5% yoy1 · 4.4% OTC revenue growth according to plan in EURm · Strong basis for Retail Media business 255 Digital Services 239 14 9 241 · Teleclinic and Retail Media together with Marketplace
Slide 7: Well on track towards EBITDA breakeven in the course of 2026
Outlook Well on track towards EBITDA breakeven in the course of 2026 Adj. FY25A FY26E EBITDA in CHFm Q1A Q2A Q3A Q4A Q1A Q2E Q3E Q4E · Ongoing adj. EBITDA improvement 10 since Q1 2025 driven by · strong operational performance · enhanced marketing efficiency · disciplined cost management 0 · CHF -6.
Slide 8: Short- and mid-term outlook fully confirmed
Outlook Short- and mid-term outlook fully confirmed External revenue1 2026 Mid-single digit to low teens in local currency Adj. EBITDA 2026 CHF -10m to - 25m Capital expenditure 2026 CHF ~30m EBITDA breakeven in the course of 2026 and positive free cashflow in the course of 2027 External revenue1 ~1
Slide 9: Proposed Board Nominees standing for expertise and independence
Annual General Meeting Proposed Board Nominees standing for expertise and independence · Existing members guarantee stability and continuity to execute strategy · Highly credible, independent Board Nominees bringing deep Prof. Dr. Andréa Belliger Walter Oberhänsli Florian Seubert expertise in Member
Slide 10: © DocMorris SA
© DocMorris SA
Slide 11: Financial calendar
Backup Financial calendar Date Event/publication 12 May 2026 Annual General Meeting 2026 19 August 2026 H1 2026 Results (incl. conference call) 15 October 2026 Q3 2026 Trading Update 4th quarter 2026 Capital Markets Day | 26Q1 Trading Update 11
Slide 12: Thank you
Thank you
Slide 13: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by DocMorris AG ("DocMorris" and conditions affecting DocMorris’ markets, and other factors beyond the control of DocMorris). together with its subsidiaries, "we", "us" or "DocMorris") solely for informational purposes and Neither D